BioVie (BIVI) news
Recent news
OLVI continuing measures to mitigate cost pressures
AInvest Wire · 2d agoOlvi changes its guidance for 2026
AInvest Wire · 2d agoBiovie - No serious adverse events reported in Bezisterim arm
Biovie Inc. (NASDAQ: BVIE) has reported that no serious adverse events were observed in the Bezisterim arm of its ongoing clinical trial, according to the company’s latest update. This development comes as part of the Phase 2b study evaluating the safety and efficacy of Bezisterim in patients with…
AInvest Wire · Sep 15, 2026Biovie - Bezisterim shows advantage over placebo on 21 of 22 endpoints in phase 2 trial
AInvest Wire · Sep 15, 2026Biovie announces topline results from phase 2 address-LC trial evaluating bezisterim for the treatment of neurological symptoms associated with long COVID
Biovie Inc. has announced topline results from the Phase 2 ADDRESS-LC trial evaluating bezisterim for the treatment of neurological symptoms associated with long COVID. The trial, described as a triple-blind study, is designed to assess safety, tolerability, and efficacy of the investigational…
AInvest Wire · Sep 15, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.